Clinical trials: Relapsing Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)
People with multiple sclerosis (MS) often experience problems with cognitive functioning, which can be debilitating and interfere with their daily functioning.
- Trial name
- NCT00914758
- Where
- 7 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Washington Neuropsychology Research Group
Multiple Sclerosis, Relapsing Remitting
Differential Immune Effects of Natalizumab
Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS).
- Trial name
- NCT00859482
- Volunteers
- 27 people
- Sponsor
- Cantonal Hospital of St. Gallen
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting
Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
RTL1000 is a new agent that has not been previously tested in humans. It is thought that RTL may specifically control the abnormal immune response or attack against the insulation on the nerves that occurs in multiple sclerosis.
- Trial name
- NCT00411723
- Testing
- RTL1000 (recombinant T cell receptor ligand)
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Artielle ImmunoTherapeutics
Relapsing Remitting Multiple Sclerosis, Sleep Initiation and Maintenance Disorders
Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)
The purpose of this study is to determine if people with multiple sclerosis (MS) and fatigue have disrupted sleep, as was suggested in previous studies, and whether treating the disruptions of sleep improves the fatigue.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Sleep Initiation and Maintenance Disorders, Fatigue
- Trial name
- NCT00594087
- Testing
- eszopiclone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Vermont
Multiple Sclerosis, Relapsing-Remitting
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
The purpose of this study is to determine whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms whether…
- Trial name
- NCT00099502
- Testing
- Interferon beta-1b (Betaferon/Betaseron, BAY86-5046), Copaxone
- Where
- 199 sites in United States, Argentina and 24 more
- Volunteers
- 2,244 people
- Sponsor
- Bayer
Relapsing Remitting Multiple Sclerosis
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
This study is to find out if starting at low dose Avonex and slowly increasing to full dose will improve flu like symptoms as a side effect of Avonex treatment.
- Trial name
- TODAY (NCT00574041)
- Testing
- Interferon beta-1a
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
AVONEX® Combination Trial - "ACT"
The purpose of this study is to determine the efficacy and safety of combination therapy with AVONEX plus low dose oral methotrexate (MTX), every other month courses of intravenous methylprednisolone (IVMP), or both in patients…
- Trial name
- NCT00112034
- Testing
- Methotrexate, IV methylprednisolone
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
The purpose of this study is to determine if BHT-3009 decreases inflammation (measured by gadolinium enhancing MRI lesions) in the brains of people with relapsing remitting multiple sclerosis.
- Trial name
- NCT00382629
- Testing
- BHT-3009 0.5 mg, BHT-3009 1.5 mg
- Volunteers
- 252 people
- Sponsor
- Bayhill Therapeutics
Relapsing-Remitting Multiple Sclerosis
Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
This study is to find out if Interferon-beta can recover its effectiveness in patients with Multiple Sclerosis who have previously developed neutralizing antibodies to Interferon-Beta.
- Trial name
- RECOVER (NCT00492466)
- Testing
- Interferon-beta-1a, methylprednisolone
- Where
- Finland
- Volunteers
- 14 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
This study was to find out if patients with Relapsing Remitting Multiple Sclerosis treated with Interferon beta-1a had an improved quality of life after treatment with Interferon beta-1a
- Trial name
- FLAIR (NCT00534261)
- Testing
- Interferon beta-1a
- Where
- 3 sites in Belgium, Luxembourg and 1 more
- Volunteers
- 284 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
Impaired short term memory, attention and concentration lapses, and slower processing of information occur in up to 40-65% of patients with Multiple Sclerosis (MS).
- Trial name
- NCT00398528
- Testing
- Glatiramer acetate, (Copaxone®), IFN-β-1a, (Avonex®)
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Neurognostics
Relapsing-Remitting Multiple Sclerosis
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
The purpose of this study is to determine if medication designed to improve memory will help patients with Multiple Sclerosis (MS) who are experiencing memory problems using fMRI to track brain activity.
- Trial name
- NCT00315367
- Testing
- Donepezil HCI (drug)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Neurognostics
Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive
Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Scientific background: Growing awareness and accumulating data regarding the cognitive impairment and its progression in multiple sclerosis (MS) patients has received an important place in neurological research in the last decade.
- Trial name
- NCT00220493
- Testing
- Ritalin
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Sheba Medical Center
Relapsing-Remitting Multiple Sclerosis
Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS
MS has been associated with fatigue, attention problems, and a number of cognitive difficulties. There is no treatment approved yet to treat these problems.
- Trial name
- NCT00210301
- Testing
- Provigil (modafinil)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Institute for Clinical Research
Relapsing-Remitting Multiple Sclerosis
Omega-3 Fatty Acid Treatment in Multiple Sclerosis
Based on previous clinical studies indicating beneficial treatment effects of omega-3 fatty acids in multiple sclerosis, and the increasing evidence of anti-inflammatory effects of omega-3 fatty acids, this study aims to evaluate…
- Trial name
- NCT00360906
- Testing
- Triomar™ (omega-3 fatty acids)
- Where
- Norway
- Volunteers
- 100 people
- Sponsor
- Haukeland University Hospital
Multiple Sclerosis, Relapsing-Remitting
Treatment of Multiple Sclerosis Using Over the Counter Inosine
The purpose of this study is to determine whether raising low levels of the natural antioxidant uric acid by the administration of a precursor, inosine, has any therapeutic effect on the progression of Relapsing Remitting…
- Trial name
- NCT00067327
- Testing
- Inosine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Relapsing-Remitting Multiple Sclerosis
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
The aim of the study is to determine whether a therapeutic strategy combining mitoxantrone and interferon beta1b can delay disease progression of at least one point on EDSS scale in patients with clinically very active…
- Trial name
- NCT00219908
- Testing
- Mitoxantrone
- Where
- 23 sites in France, Italy
- Volunteers
- 124 people
- Sponsor
- Rennes University Hospital
Relapsing Remitting Multiple Sclerosis
A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis
The purpose of this study is to determine if using Avonex in combination with Zocor is a safe and effective therapy for subjects with relapsing remitting multiple sclerosis.
- Trial name
- NCT00242268
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alabama Neurology Associates, PC
Multiple Sclerosis
A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction ( a measure of brain shrinkage) and by clinical…
- Trial name
- NCT00217295
- Testing
- Avonex and Topamax
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Multiple Sclerosis Institute